MedWorm provides a medical RSS filtering service. Over 6000 RSS medical sources are combined and output via different filters. This feed contains the latest medical blog items that have been tagged with 'androgen deprivation therapy'. Sat, 03 Sep 2011 02:59:53 +0100 http://www.medworm.com/index.php?rid=4151792&cid=t_156564_87_f&fid=39187&url=http%3A%2F%2Fgetbetterhealth.com%2Fwhen-doctors-are-paid-less-unnecessary-prescriptions-drop%2F2010.11.09 Take medical uncertainty. Add financial incentive to treat. Voila! Increased utilization. Now take away financial incentive to treat. Guess what you get? MedPageToday explains, in the case of hormone therapy for prostate cancer: Medicare accomplished what clinical guidelines and evidence-based medicine couldn’t: it reduced unnecessary use of androgen deprivation therapy (ADT) in prostate cancer. Inappropriate use decreased by almost 30% from 2003 to 2005, following enactment of the Medicare Modernization Act, which lowered physician reimbursement for ADT. Appropriate use of ADT did not change during the same time period, according to an article in the Nov. 4 issue of the New England Journal of Medicine. “Our findings suggest that reductions in reimbursement may influence the de... Better Health blogs http://www.medworm.com/rss/comments.php?id=4151792 Tue, 09 Nov 2010 19:00:48 +0100 4151792 http://www.medworm.com/index.php?rid=1623065&cid=t_156564_136_f&fid=36051&url=http%3A%2F%2Ffeeds.b5media.com%2F%7Er%2Fb5media%2FCancerCommentary%2F%7E3%2F335918405%2F In this study of more than 1,400 men, denosumab treatment produced statistically significantly greater increases in bone mineral density (BMD) at the lumbar spine (primary endpoint) and non-vertebral sites compared with placebo at multiple time points. These improvements in BMD were consistent with those seen in other denosumab studies evaluating BMD in women with breast cancer receiving aromatase inhibitor therapy, and in post-menopausal women with low bone mass. During the 36-month evaluation period, men receiving denosumab experienced less than half the incidence of new vertebral fractures (a secondary endpoint) compared with those receiving placebo, a statistically significant finding. Furthermore, in the denosumab arm there were fewer non-vertebral fractures over the 36-month period. ... Cancer Commentary blogs http://www.medworm.com/rss/comments.php?id=1623065 Tue, 15 Jul 2008 09:26:13 +0100 1623065 http://www.medworm.com/index.php?rid=1129518&cid=t_156564_136_f&fid=36051&url=http%3A%2F%2Ffeeds.b5media.com%2F%7Er%2Fb5media%2FCancerCommentary%2F%7E3%2F210922900%2F This study demonstrates that the benefits of short-term hormonal therapy for men receiving radiation therapy for prostate cancer far outweigh the risks. While four months of hormonal therapy isn’t enough to cause significant side effects, we found that it can delay the development of bone metastasis by as many as eight years, which is very significant. So by taking a little bit of hormonal therapy early, patients may avoid having to take a lot of it later.” The study is published online January 2 in the Journal of Clinical Oncology. Find more details from American Society of Clinical Oncology. Share This (Source: Cancer Commentary) Cancer Commentary blogs http://www.medworm.com/rss/comments.php?id=1129518 Fri, 04 Jan 2008 05:06:23 +0100 1129518 http://www.medworm.com/index.php?rid=1027424&cid=t_156564_107_f&fid=36585&url=http%3A%2F%2Ffeeds.feedburner.com%2F%7Er%2FHighlightHealth%2F%7E3%2F184703435%2F This article was published on Highlight HEALTH. (Source: Highlight HEALTH) Highlight HEALTH blogs http://www.medworm.com/rss/comments.php?id=1027424 Wed, 14 Nov 2007 16:35:25 +0100 1027424